Login to Your Account

GSK, Theravance's Breo Wins Advisory Panel Nod in COPD

By Randy Osborne
Staff Writer

Wednesday, April 17, 2013
The FDA's Pulmonary-Allergy Drugs Advisory Committee gave its blessing to inhaled Breo (fluticasone furoate [FF]/vilanterol [VI]), the combination corticosteroid and long-acting beta2 agonist (LABA) for chronic obstructive pulmonary disease (COPD) from GlaxoSmithKline plc and Theravance Inc., though voting across several categories was mixed.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription